Targeted treatment of esophagogastric cancer
Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 22, 2016
|
| In: |
Oncology research and treatment
Year: 2016, Volume: 39, Issue: 12, Pages: 788-794 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000452877 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1159/000452877 Verlag, Volltext: https://www-karger-com.ezproxy.medma.uni-heidelberg.de/Article/FullText/452877 
|
| Author Notes: | Hans-Georg Kopp, Ralf-Dieter Hofheinz |
| Summary: | Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel. Herein, we give an overview of currently approved targeted treatments for locally advanced/resectable as well as unresectable/metastatic EGJ/gastric adenocarcinoma, summarizing the underlying clinical studies. Moreover, further potential targets still under investigation are presented. |
|---|---|
| Item Description: | Gesehen am 07.02.2019 |
| Physical Description: | Online Resource |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000452877 |